p53 and ATF4 mediate distinct and additive pathways to skeletal muscle atrophy during limb immobilization

American Journal of Physiology - Endocrinology and Metabolism

Volumn 307, Issue 3, 2014, Pages

  Fox, Daniel K ^a   Ebert, Scott M ^a   Bongers, Kale S ^a   Dyle, Michael C ^a   Bullard, Steven A ^a,b   Dierdorff, Jason M ^a   Kunkel, Steven D ^a   Adams, Christopher M ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Activating transcription factor 4; Immobilization; p21; p53; Skeletal muscle; Skeletal muscle atrophy

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; MESSENGER RNA; PROTEIN P53; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENETIC ASSOCIATION; IMMOBILIZATION; MOUSE; MUSCLE ATROPHY; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; SKELETAL MUSCLE ATROPHY;

ACTIVATING TRANSCRIPTION FACTOR 4; IMMOBILIZATION; P21; P53; SKELETAL MUSCLE; SKELETAL MUSCLE ATROPHY;

ACTIVATING TRANSCRIPTION FACTOR 4; AMINO ACID SUBSTITUTION; ANIMALS; CROSSES, GENETIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE RESISTANCE; GENOME-WIDE ASSOCIATION STUDY; HINDLIMB SUSPENSION; IMMOBILIZATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MICRORNAS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; MUTANT PROTEINS; PROMOTER REGIONS, GENETIC; RECOMBINANT PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84907220805     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00010.2014     Document Type: Article

References (68)

1. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400-414, 2009.
2. Appell HJ. Skeletal muscle atrophy during immobilization. Int J Sports Med 7: 1-5, 1986.
3. Banduseela VC, Ochala J, Chen YW, Goransson H, Norman H, Radell P, Eriksson LI, Hoffman EP, Larsson L. Gene expression and muscle fiber function in a porcine ICU model. Physiol Genomics 39: 141-159, 2009.
4. Bodine SC. Disuse-induced muscle wasting. Int J Biochem Cell Biol 45: 2200-2208, 2013.
5. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704-1708, 2001.
6. Bongers KS, Fox DK, Ebert SM, Kunkel SD, Dyle MC, Bullard SA, Dierdorff JM, Adams CM. Skeletal muscle denervation causes skeletal muscle atrophy through a pathway that involves both Gadd45a and HDAC4. Am J Physiol Endocrinol Metab 305: E907-E915, 2013.
7. Brooke MH, Kaiser KK. Three "myosin adenosine triphosphatase" systems: the nature of their pH lability and sulfhydryl dependence. J Histochem Cytochem 18: 670-672, 1970.
8. Bruning JC, Michael MD, Winnay JN, Hayashi T, Horsch D, Accili D, Goodyear LJ, Kahn CR. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 2: 559-569, 1998.
9. Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134: 451-460, 2008.
10. Caron AZ, Drouin G, Desrosiers J, Trensz F, Grenier G. A novel hindlimb immobilization procedure for studying skeletal muscle atrophy and recovery in mouse. J Appl Physiol 106: 2049-2059, 2009.
11. Carrier F, Smith ML, Bae I, Kilpatrick KE, Lansing TJ, Chen CY, Engelstein M, Friend SH, Henner WD, Gilmer TM, Kastan MB, Fornace AJ Jr. Characterization of human Gadd45, a p53-regulated protein. J Biol Chem 269: 32672-32677, 1994.
12. Cohn RD, Henry MD, Michele DE, Barresi R, Saito F, Moore SA, Flanagan JD, Skwarchuk MW, Robbins ME, Mendell JR, Williamson RA, Campbell KP. Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell 110: 639-648, 2002.
13. de Vries A, Flores ER, Miranda B, Hsieh HM, van Oostrom CT, Sage J, Jacks T. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci USA 99: 2948-2953, 2002.
14. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684, 1995.
15. Dreyer HC, Strycker LA, Senesac HA, Hocker AD, Smolkowski K, Shah SN, Jewett BA. Essential amino acid supplementation in patients following total knee arthroplasty. J Clin Invest 123: 4654-4666, 2013.
16. Dubowitz V, Sewry CA. Muscle Biopsy: A Practical Approach. Philadelphia, PA: Saunders/Elsevier, 2007, p. xiii, 611.
17. Ebert SM, Dyle MC, Kunkel SD, Bullard SA, Bongers KS, Fox DK, Dierdorff JM, Foster ED, Adams CM. Stress-induced skeletal muscle Gadd45a expression reprograms myonuclei and causes muscle atrophy. J Biol Chem 287: 27290-27301, 2012.
18. Ebert SM, Monteys AM, Fox DK, Bongers KS, Shields BE, Malmberg SE, Davidson BL, Suneja M, Adams CM. The transcription factor ATF4 promotes skeletal myofiber atrophy during fasting. Mol Endocrinol 24: 790-799, 2010.
19. Edwards MG, Anderson RM, Yuan M, Kendziorski CM, Weindruch R, Prolla TA. Gene expression profiling of aging reveals activation of a p53-mediated transcriptional program. BMC Genomics 8: 80, 2007.
20. Ehrnhoefer DE, Skotte NH, Ladha S, Nguyen YT, Qiu X, Deng Y, Huynh KT, Engemann S, Nielsen SM, Becanovic K, Leavitt BR, Hasholt L, Hayden MR. p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin. Hum Mol Genet 23: 717-729, 2014.
21. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
22. el-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, Kinzler KW, Vogelstein B. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55: 2910-2919, 1995.
23. Fiscella M, Ullrich SJ, Zambrano N, Shields MT, Lin D, Lees-Miller SP, Anderson CW, Mercer WE, Appella E. Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene 8: 1519-1528, 1993.
24. Gonzalez de Aguilar JL, Niederhauser-Wiederkehr C, Halter B, De Tapia M, Di Scala F, Demougin P, Dupuis L, Primig M, Meininger V, Loeffler JP. Gene profiling of skeletal muscle in an amyotrophic lateral sclerosis mouse model. Physiol Genomics 32: 207-218, 2008.
25. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, Sadri N, Yun C, Popko B, Paules R, Stojdl DF, Bell JC, Hettmann T, Leiden JM, Ron D. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 11: 619-633, 2003.
26. Hill R, Bodzak E, Blough MD, Lee PW. p53 Binding to the p21 promoter is dependent on the nature of DNA damage. Cell Cycle 7: 2535-2543, 2008.
27. Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. Oncogene 26: 1306-1316, 2007.
28. Huang Q, Raya A, DeJesus P, Chao SH, Quon KC, Caldwell JS, Chanda SK, Izpisua-Belmonte JC, Schultz PG. Identification of p53 regulators by genome-wide functional analysis. Proc Natl Acad Sci USA 101: 3456-3461, 2004.
29. Ibebunjo C, Chick JM, Kendall T, Eash JK, Li C, Zhang Y, Vickers C, Wu Z, Clarke BA, Shi J, Cruz J, Fournier B, Brachat S, Gutzwiller S, Ma Q, Markovits J, Broome M, Steinkrauss M, Skuba E, Galarneau JR, Gygi SP, Glass DJ. Genomic and proteomic profiling reveals reduced mitochondrial function and disruption of the neuromuscular junction driving rat sarcopenia. Mol Cell Biol 33: 194-212, 2013.
30. Ishido M, Kami K, Masuhara M. In vivo expression patterns of MyoD, p21, and Rb proteins in myonuclei and satellite cells of denervated rat skeletal muscle. Am J Physiol Cell Physiol 287: C484-C493, 2004.
31. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell 71: 587-597, 1992.
32. Kelleher AR, Kimball SR, Dennis MD, Schilder RJ, Jefferson LS. The mTORC1 signaling repressors REDD1/2 are rapidly induced and activation of p70S6K1 by leucine is defective in skeletal muscle of an immobilized rat hindlimb. Am J Physiol Endocrinol Metab 304: E229-E236, 2013.
33. Kruse JP, Gu W. Modes of p53 regulation. Cell 137: 609-622, 2009.
34. Kunkel SD, Suneja M, Ebert SM, Bongers KS, Fox DK, Malmberg SE, Alipour F, Shields RK, Adams CM. mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metab 13: 627-638, 2011.
35. Laure L, Suel L, Roudaut C, Bourg N, Ouali A, Bartoli M, Richard I, Danièle N. Cardiac ankyrin repeat protein is a marker of skeletal muscle pathological remodelling. FEBS J 276: 669-684, 2009.
36. Liu DX, Lobie PE. Transcriptional activation of p53 by Pitx1. Cell Death Differ 14: 1893-1907, 2007.
37. Llano-Diez M, Gustafson AM, Olsson C, Goransson H, Larsson L. Muscle wasting and the temporal gene expression pattern in a novel rat intensive care unit model. BMC Genomics 12: 602, 2011.
38. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9: 935-944, 1995.
39. Maddocks OD, Vousden KH. Metabolic regulation by p53. J Mol Med 89: 237-245, 2011.
40. Mahmoudi S, Henriksson S, Corcoran M, Mendez-Vidal C, Wiman KG, Farnebo M. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell 33: 462-471, 2009.
41. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 14: 994-1004, 2000.
42. Mazan-Mamczarz K, Galban S, Lopez de Silanes I, Martindale JL, Atasoy U, Keene JD, Gorospe M. RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc Natl Acad Sci USA 100: 8354-8359, 2003.
43. Meier W, Mizner RL, Marcus RL, Dibble LE, Peters C, Lastayo PC. Total knee arthroplasty: muscle impairments, functional limitations, and recommended rehabilitation approaches. J Orthop Sports Phys Ther 38: 246-256, 2008.
44. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 274: 36031-36034, 1999.
45. Petterson SC, Mizner RL, Stevens JE, Raisis L, Bodenstab A, Newcomb W, Snyder-Mackler L. Improved function from progressive strengthening interventions after total knee arthroplasty: a randomized clinical trial with an imbedded prospective cohort. Arthritis Rheum 61: 174-183, 2009.
46. Proud CG. eIF2 and the control of cell physiology. Semin Cell Dev Biol 16: 3-12, 2005.
47. Puzio-Kuter AM. The Role of p53 in Metabolic Regulation. Genes Cancer 2: 385-391, 2011.
48. Raman V, Martensen SA, Reisman D, Evron E, Odenwald WF, Jaffee E, Marks J, Sukumar S. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 405: 974-978, 2000.
49. Sacheck JM, Hyatt JP, Raffaello A, Jagoe RT, Roy RR, Edgerton VR, Lecker SH, Goldberg AL. Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J 21: 140-155, 2007.
50. Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R, Sandri M. Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol 296: C1248-C1257, 2009.
51. Schwarzkopf M, Coletti D, Marazzi G, Sassoon D. Chronic p53 activity leads to skeletal muscle atrophy and muscle stem cell perturbation. Basic Appl Myol 18: 131-138, 2009.
52. Schwarzkopf M, Coletti D, Sassoon D, Marazzi G. Muscle cachexia is regulated by a p53-PW1/Peg3-dependent pathway. Genes Dev 20: 3440-3452, 2006.
53. Shadfan M, Lopez-Pajares V, Yuan ZM. MDM2 and MDMX: Alone and together in regulation of p53. Transl Cancer Res 1: 88-89, 2012.
54. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334, 1997.
55. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11: 3471-3481, 1997.
56. Siu F, Bain PJ, LeBlanc-Chaffin R, Chen H, Kilberg MS. ATF4 is a mediator of the nutrient-sensing response pathway that activates the human asparagine synthetase gene. J Biol Chem 277: 24120-24127, 2002.
57. Siu PM, Alway SE. Id2 and p53 participate in apoptosis during unloading-induced muscle atrophy. Am J Physiol Cell Physiol 288: C1058-C1073, 2005.
58. Siu PM, Alway SE. Mitochondria-associated apoptotic signalling in denervated rat skeletal muscle. J Physiol 565: 309-323, 2005.
59. Stevenson EJ, Giresi PG, Koncarevic A, Kandarian SC. Global analysis of gene expression patterns during disuse atrophy in rat skeletal muscle. J Physiol 551: 33-48, 2003.
60. Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 123: 49-63, 2005.
61. Vandenborne K, Elliott MA, Walter GA, Abdus S, Okereke E, Shaffer M, Tahernia D, Esterhai JL. Longitudinal study of skeletal muscle adaptations during immobilization and rehabilitation. Muscle Nerve 21: 1006-1012, 1998.
62. Vilborg A, Glahder JA, Wilhelm MT, Bersani C, Corcoran M, Mahmoudi S, Rosenstierne M, Grander D, Farnebo M, Norrild B, Wiman KG. The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element. Proc Natl Acad Sci USA 106: 15756-15761, 2009.
63. Welle S, Brooks AI, Delehanty JM, Needler N, Bhatt K, Shah B, Thornton CA. Skeletal muscle gene expression profiles in 20-29 year old and 65-71 year old women. Exp Gerontol 39: 369-377, 2004.
64. Welle S, Brooks AI, Delehanty JM, Needler N, Thornton CA. Gene expression profile of aging in human muscle. Physiol Genomics 14: 149-159, 2003.
65. Yu Y, Zhang D, Huang H, Li J, Zhang M, Wan Y, Gao J, Huang C. NF-kappa B1 p50 promotes p53 protein translation through miR-190 downregulation of PHLPP1. Oncogene 33: 996-1005, 2014.
66. Zhan Q. Gadd45a, a p53-and BRCA1-regulated stress protein, in cellular response to DNA damage. Mutat Res 569: 133-143, 2005.
67. Zhang M, Zhang J, Chen X, Cho SJ, Chen X. Glycogen synthase kinase 3 promotes p53 mRNA translation via phosphorylation of RNPC1. Genes Dev 27: 2246-2258, 2013.
68. Zou T, Mazan-Mamczarz K, Rao JN, Liu L, Marasa BS, Zhang AH, Xiao L, Pullmann R, Gorospe M, Wang JY. Polyamine depletion increases cytoplasmic levels of RNA-binding protein HuR leading to stabilization of nucleophosmin and p53 mRNAs. J Biol Chem 281: 19387-19394, 2006.